随机临床试验:贝雷克坦(牛源性肺表面活性剂)和泊拉坦(猪源性肺表面活性剂)治疗新生儿呼吸窘迫综合征的疗效比较

• 作 者: Malloy C.A. Nicoski P. Muraskas J.K. 朱新菊
• 机 构: Department of Pediatrics Neonatology Loyola University Medical Center 2160 South First Avenue Maywo
• 出 处: 世界核心医学期刊文摘(儿科学分册)
• 发表日期: 2005年11期
• 关键词: 拉坦 肺表面活性剂 贝雷 随机临床试验 猪源 平均胎龄 平均出生体重 动脉导管未闭 氧分压 表面活性剂

Aim: To compare the effects of beractant and poractant in neonatal respiratory distress syndrome (RDS). Methods: Infants with RDS were randomized to receive beractant or poractant. The primary outcome measure was fraction of inspired oxygen (FiO2) requirement in the first 48 h after surfactant therapy. Results: 58 infants completed the study. The mean gestational ages for the poractant and beractant groups were 29.6 ±3.6 and 29.3 ±2.9 wk, with average birthweights of 1394 ±699 and 1408 ±534 g, respectively. In the first 48 h, infants who received poractant had a lower FiO2 requirement compared to those who received beractant (p = 0.018). The prevalence of patent ductus arteriosus (PDA) was lower in the group of infants that received poractant (17%) compared to the group that received beractant (45%) (p = 0.02). Conclusions: Infants with RDS treated with poractant had a lower FiO2 requirement during the first 48 h compared to infants who received beractant. Infants who received poractant also had fewer PDAs than infants who received beractant. The difference in FiO2 was not associated with a difference in age of first extubation, total intubation time, or incidence of bronchopulmonary dysplasia between groups.

Aim: To compare the effects of beractant and poractant in neonatal respiratory distress syndrome (RDS). Methods: Infants with RDS were randomized to receive beractant or poractant. The primary outcome measure was fraction of inspired oxygen (FiO2) requirement in the first 48 h After surfactant therapy. The mean gestational ages for the poractant and beractant groups were 29.6 ± 3.6 and 29.3 ± 2.9 wk, with average birthweights of 1394 ± 699 and 1408 ± 534 g, respectively. In the first 48 h, infants who received poractant had a lower FiO2 requirement compared to those who received beractant (p = 0.018). The prevalence of patent ductus arteriosus (PDA) was lower in the group of infants that received poractant (17%) compared to the Group that received beractant (45%) (p = 0.02). Conclusions: Infants with RDS treated with poractant had a lower FiO2 requirement during the first 48 h compared to infants who received beractant. Infants who received pora The difference in FiO2 was not associated with a difference in age of first extubation, total intubation time, or incidence of bronchopulmonary dysplasia between groups. ctant also had fewer PDAs than infants who received beractant